Matinas BioPharma

MTNB

US5768103039

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:41:50 2026-09-23 EDT			5-day change	1st Jan Change
0.1750 ^USD	-1.13%		+6.00%	-70.14%

08-20	Top Premarket Decliners	MT
08-13	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Top Premarket Decliners

Published on 08/20/2026 at 07:39 am EDT

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Matinas BioPharma

08-20	Top Premarket Decliners	MT
08-13	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-14	Top Premarket Decliners	MT
07-13	Azurity Pharmaceuticals, Inc. entered into the stock purchase agreement to acquire Matinas Biopharma Nanotechnologies, Inc. from Matinas BioPharma Holdings, Inc. (NYSEAM : MTNB) for $21.5 million.	CI
07-13	Matinas BioPharma to Merge With GH Power; Signs Deal to Sell Subsidiary, Lead Product Candidate	MT
06-16	Matinas BioPharma Files $150 Million Mixed Shelf Registration	MT
05-08	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Matinas BioPharma Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
01-23	Matinas BioPharma Holdings Inc Keith Kucinski resigns as CFO effective January 17, 2026	RE
01-23	Jerome D. Jabbour to Assume the Duties of Principal Accounting Officer of Matinas BioPharma Holdings, Inc	CI
01-23	Matinas Biopharma Holdings, Inc. Appoints Jerome D. Jabbour as Interim Chief Financial Officer, Effective January 22, 2026	CI
11-21	Matinas Biopharma Holdings Inc - CFO Keith Kucinski resigns effective January 17, 2026 - SEC filing	RE
11-21	Matinas BioPharma Holdings, Inc. Announces Resignation of Keith Kucinski as Chief Financial Officer , Effective January 17, 2026	CI
11-10	Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-28 Significant Split/Dividend

More about the company